GEN News Highlights

Synageva BioPharma has moved into larger office and laboratory premises in Lexington, MA. The firm says the bigger headquarters will allow it to broaden its discovery and translational research capabilities. “Over the last two years we have developed a pipeline of novel therapeutics for a variety of rare diseases, including lysosomal storage disorders and other genetic conditions for which there are currently no approved treatments,” remarks Sanj K. Patel, president and CEO. “The move is an important step toward ensuring the successful development of our lead program as well as advancing other pipeline programs.”

Synageva is dedicated to the discovery and development of treatments for rare diseases. The firm’s lead candidate, SBC-102, is a recombinant enzyme-replacement therapy for lysosomal acid lipase deficiency; it is moving into clinical development. Orphan drug designation for the treatment was granted by FDA in July. Synageva has four earlier-stage orphan products in development, targeting two lysosomal storage disorders, a metabolic disorder, and a genetic disease.

The firm claims its Synageva Expression Platform (SEP™) demonstrates advantages over current expression methods for therapeutic proteins. SEP hinges on a proprietary vector technology that Synegeva maintains has achieved protein-expression levels of about 14 g/L. The platform can be used to generate monoclonal antibodies, fusion proteins, cytokines, and therapeutic enzymes. It has also formed the production platform for products under evaluation in global Phase II trials, the company points out.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

GEN Poll

Secure Science

Should bans on science education, of the sort imposed on Iranians hoping to study physics and engineering in the United States, encompass other nationals and other fields of study, including biotechnology?

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

57.3%

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.